Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Ivosidenib and Combination Chemotherapy (mFOLFIRINOX) for the Treatment of Resectable Pancreatic Cancer

Trial Status: closed to accrual

This phase I trial tests the safety, side effects, and best dose of ivosidenib with modified FOLFIRINOX in treating patients with pancreatic cancer that can be removed by surgery (resectable). Ivosidenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as oxaliplatin, leucovorin calcium, irinotecan hydrochloride, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ivosidenib with modified FOLFIRINOX regimen may help control resectable pancreatic cancer.